Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 41Lung Neoplasms 11Lymphoma, Large-Cell, Anaplastic 8Neoplasm Metastasis 7Multiple Myeloma 6Lymphoma 6Neoplasms 5Colorectal Neoplasms 4Adenocarcinoma 4Uveal Melanoma 3Neuroblastoma 3Melanoma 3Hematologic Neoplasms 3Granuloma, Plasma Cell 3Carcinoma, Renal Cell 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Recurrence 2Glioma 2Glioblastoma 2Carcinoma, Squamous Cell 2Carcinoma, Hepatocellular 2Carcinoma 2Breast Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1

Interventions

Surveys and Questionnaires 4pazopanib 3Erlotinib Hydrochloride 3Cetuximab 3Vorinostat 2Oxaliplatin 2Bevacizumab 2Azacitidine 2temsirolimus 1satraplatin 1ridaforolimus 1ixazomib 1X-Rays 1Videotape Recording 1Valproic Acid 1Trastuzumab 1Sugars 1Sorafenib 1Platinum 1Pemetrexed 1Magnetic Resonance Spectroscopy 1Leucovorin 1Lenalidomide 1Lapatinib 1LY 2275796 1Injections, Subcutaneous 1Fluorouracil 1Everolimus 1Curcumin 1Crizotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Advanced Cancers × Crizotinib × Clear all
NCT01548144 2021-09-13

Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer

M.D. Anderson Cancer Center

Phase 1 Terminated
178 enrolled

Advanced Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡